GC012F (AZD0120)

A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma

Near Add Your Location

Sorting 4 by

New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
  • Accepting patients
City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Not yet accepting
Tennessee Oncology - Hayes
Nashville, TN
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.